

GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE
LOK SABHA

UNSTARRED QUESTION NO. 1986
TO BE ANSWERED ON THE 30th JULY, 2021
“COVID-19 Vaccination Drive”

1986. SHRI BHARTRUHARI MAHTAB:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether the Government has taken note that COVID-19 vaccination drive was halted in 24 out of 30 districts of Odisha due to depleted vaccine stocks in the State;
- (b) if so, the details thereof;
- (c) whether the State Government of Odisha had requested additional allocation of 15 lakh doses of Covishield to manage smooth vaccination drive; and
- (d) if so, the details thereof along with steps taken by the Government to timely replenish vaccine stocks?

ANSWER

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE
(DR. BHARATI PRAVIN PAWAR)

(a) to (d) Government of India has been providing free supply of Covid vaccines in enough quantity to States/UTs for administration to prioritized beneficiaries as recommended by NEGVAC. Various State/UTs including state of Odisha from time to time request the Union Government for additional supply of vaccine doses. Advance visibility of vaccine allocations i.e. the total doses of Covid vaccine that would be available to State/UT, are provided 15 days in advance to all States/UTs so as to enable them to prepare plan for acceleration of Covid vaccination coverage while being cognizant of the total availability of Covid vaccines

In addition, Government of India has taken many steps to augment the domestic manufacturing capacity of COVID-19 vaccines. These include support to M/s Bharat Biotech and three Public Sector Enterprises (PSEs) under ‘Mission COVID Suraksha-the Indian COVID-19 Vaccine Development Mission’, technology transfer for Covaxin production, financial assistance to one of the domestic vaccine manufacturers for ‘At-risk manufacturing’, advance payment against the supply orders placed with M/s Serum Institute of India and M/s Bharat Biotech, and streamlining of regulatory norms for approval of vaccines.